Wire · opportunities
BlueWind Medical receives FDA clearance for Revi Extend implant - Med-Tech Insights
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 12 August 2026 · Fusion42 review
BlueWind Medical received FDA 510(k) clearance for its Revi Extend implant, an advancement in implantable tibial neuromodulation for urgency urinary incontinence, with a planned limited U.S. launch in Q4 2026.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can now explore the U.S. market with the Revi Extend implant cleared to sell, meaning regulatory barriers for tibial neuromodulation devices are lower. Prepare to engage U.S. urology providers and patients as this approval opens a fresh sales opportunity.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics
MedtechFDA-clearanceimplantable-deviceurologymedtechregulatory-approval